A Randomised, Double-blind, Phase I/II Study to Evaluate the PK, PD, Safety, and Efficacy Between HLX01 and Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis and Inadequate Response to Treatment With DMARDs

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2017
To compare the PK profiles of HLX01 and Rituximab in Chinese patients with moderate to severe rheumatoid arthritis.
Epistemonikos ID: 33c4d2eece59f44157e5467bbfc5ce8a0cb06d96
First added on: Mar 23, 2022